Phase 3 trial evaluated two subcutaneous BRIUMVI dosing regimens; administration every 2 months or every 3 monthsTop-line data expected year-end ...

A phase 3 trial of patients with moderate-to-severe TED has shown that subcutaneous injection of Tepezza by way of an on-body ...

Health Canada has granted a Notice of Compliance (NOC) for Saphnelo® (anifrolumab injection) for subcutaneous self-administration via a single-use autoinjector for adult patients with active, ...

In this segment, Ms. Popolo discusses the practical and logistical differences between intravenous and subcutaneous ...

In this segment, Dr. Morrison discusses the clinical evidence supporting subcutaneous immunotherapy and explains the concept ...

Amgen (NASDAQ: AMGN) today announced positive topline results from a Phase 3 trial of TEPEZZA (teprotumumab-trbw) administered by subcutaneous injection via an on-body injector (OBI) in participants ...

A subcutaneous version of the newly approved Alzheimer's drug lecanemab (Leqembi) may be on the horizon. Weekly subcutaneous lecanemab 100 mg/mL injection appeared to be as effective at amyloid plaque ...

On-body injector delivery of subcutaneous teprotumumab achieves clinically meaningful proptosis reduction in phase 3 thyroid eye disease study.

The trial met its primary endpoint, demonstrating a statistically significant 77% proptosis response rate at 24 weeks.

In the new subcutaneous drug delivery landscape, the growing trend towards patient-friendly, at-home administration is ...

Please provide your email address to receive an email when new articles are posted on . Subcutaneous delivery reduced administration time from several hours to less than 5 minutes. Although unexpected ...